

Pharmaco-metabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine

Authors: Alexandra Backshall^{1*}, Rohini Sharma^{2*}, Stephen J. Clarke³, Hector C. Keun¹

¹Biomolecular Medicine, Dept of Surgery & Cancer, Faculty of Medicine, Imperial College London South Kensington Campus, Exhibition Rd, London SW7 2AZ, UK

²Division of Investigative Sciences, Imperial College London Hammersmith Campus, Du Cane Road, London W12 ONN, UK

³Department of Medical Oncology, University of Sydney Concord Hospital, Concord, Sydney, NSW2137, Australia

*AB and RS are joint first authors

Correspondence/reprints: Dr Hector Keun

Address: Biomolecular Medicine, Dept of Surgery & Cancer, Faculty of Medicine, Imperial College London South Kensington Campus, Exhibition Rd, London SW7 2AZ, UKE-mail: h.keun@imperial.ac.uk

Tel: +44 (0)20 7594 3161

Fax: +44 (0)20 7594 3226

Running title: Pharmaco-metabonomics of capecitabine toxicity

Key words: pharmaco-metabonomics, colorectal cancer, toxicity, capecitabine, NMR

STATEMENT OF TRANSLATIONAL RELEVANCE

In patients undergoing chemotherapy systemic toxicity remains the major limitation to adequate dosing. The ability to predict adverse events prior to drug administration, and to provide individualized treatment, is likely to have a significant impact on clinical outcomes and quality of life, particularly in the palliative setting. ‘Pharmaco-metabonomics’ - using pre-treatment profiles of endogenous metabolite levels to predict the metabolic fate and toxicity of drugs - potentially offers phenotypic information not captured by genetic profiling. A patient’s response to treatment relies on a complex array of genetic and environmental factors and this approach has the ability to identify in a non-invasive manner a downstream profile that describes the ‘current state’ biological system, beyond the potential state defined by the genome. In the future models based on the combination of both pharmaco-genetic and pharmaco-metabonomic information using up- and down-stream data can help delineate the optimum therapeutic pathway for the individual patient.

Abstract

Purpose: Endogenous metabolic profiles have been shown to predict the fate and toxicity of drugs such as acetaminophen in healthy individuals. However, the clinical utility of metabonomics in oncology remains to be defined. We aimed to evaluate the effect of pre-treatment serum metabolic profiles generated by ^1H NMR spectroscopy on toxicity in patients with inoperable colorectal cancer receiving single agent capecitabine.

Experimental Design: Serum was collected from 54 patients with a diagnosis of locally advanced or metastatic colorectal cancer prior to treatment with single agent capecitabine. ^1H NMR spectroscopy was used to generate metabolic profile data for each patient. Toxicities were graded according to National Cancer Institute Common Toxicity Criteria version 2.0.

Results: Higher levels of LDL-derived lipids, including polyunsaturated fatty acids and choline phospholipids predicted for higher-grade toxicity over the treatment period. Statistical analyses revealed a ‘pharmaco-metabonomic’ lipid profile that correlated with severity of toxicity.

Conclusions: This study suggests that metabolic profiles can delineate sub-populations susceptible to adverse events and have a potential role in the assessment of treatment viability for cancer patients prior to commencing chemotherapy.

Introduction

Metabolic profiling (metabonomics/metabolomics) is a flexible approach that can be used to investigate in a systematic manner the metabolic composition of cells, tissues and biofluids (1-4). It has recently been demonstrated that pre-treatment biofluid metabolic profiles can be used to predict the metabolic fate and toxicity of drugs *in vivo*, specifically for acetaminophen exposure in rodents (5), an observation subsequently shown to translate to man (6, 7). This strategy, termed ‘pharmaco-metabonomics’, potentially offers phenotypic information not captured by genetic profiling that can be used to predict pharmacology. In the study by Winnike et al. (7) a combination of both the early drug metabolite profile and observed changes in common urinary endogenous metabolites were able to identify a subpopulation of individuals who experienced ALT elevation in response to 4g/day acetaminophen, several days before the phenotype was apparent by conventional clinical chemistry.

While this experiment shows in principle how pharmaco-metabonomics could help to reduce adverse events in susceptible individuals, the trial was conducted in otherwise healthy volunteers with no clinical requirement for treatment. In patients undergoing chemotherapy systemic toxicity remains the major limitation to adequate dosing. The ability to predict adverse events prior to drug administration, and to provide individualized treatment, is likely to have a significant impact on clinical outcomes and quality of life, particularly in the palliative setting. While extensively used to characterise the tumour metabolome (8-10) and for the discovery of diagnostic biomarkers in body fluids (11, 12), there are relatively few examples of metabolic profiling being used to derive prognostic or predictive biofluid biomarkers in oncology (13). In a previous study we used an NMR-based approach to define a serum metabolic signature predictive of weight gain secondary to chemotherapy in patients with breast cancer,

demonstrating that this platform can potentially identify phenotypes related to poorer outcomes (14). However, the utility of an NMR-based approach as a prognostic or predictive marker of clinical outcome remains to be evaluated.

Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) which was designed to minimize gastrointestinal toxicity whilst maintaining anti-tumour activity. The pharmacologically inactive capecitabine is absorbed from the gastrointestinal tract and undergoes a three-step activation process to 5-FU within the tumour (15). During the first step, capecitabine is converted to 5'-deoxy-5-fluorocytidine by carboxylesterases primarily in the liver (15-18). This is then converted to 5'-Deoxy-5-fluorouridine (5'-DFUR) by cytidine deaminase within the liver and tumour tissue. In the final step, 5-FU is ultimately formed from 5'-DFUR by thymidine phosphorylase, an enzyme that is predominant in tumour tissues. This process results in improved bioavailability of 5-FU by reducing the catabolism of 5-FU in the liver; and leads to higher intra-tumoural 5-FU delivery. The intermediate, 5'-DFUR, is toxic in itself causing diarrhoea through formation of 5-FU as a result of metabolism by thymidine phosphorylase present in the small intestinal mucosa. Capecitabine has been shown to have equivalent efficacy in the management of colorectal cancer in both the metastatic and adjuvant setting (19-23). The dose-limiting side-effects are diarrhoea, stomatitis and palmar-plantar erythema. The aim of this study was to determine whether a pre-treatment serum metabolic profile could predict toxicity from capecitabine in patients with advanced colorectal cancer.

Materials and Methods

Patients. The study was conducted as part of a previously published trial assessing the tolerability of fixed dose capecitabine (24). Consenting patients with locally advanced or metastatic colorectal inoperable cancer with measurable or evaluable disease who had adequate organ function and performance status were enrolled from three centers in Australia between January 2002 and August 2003. Each patient received single agent capecitabine 2000mg twice daily. The efficacy data of fixed-dose capecitabine have been published elsewhere (24).

Evaluation of patients. Complete history was recorded, full physical examination performed, and blood samples collected at baseline. Baseline computed tomography imaging of the chest, abdomen and pelvis were obtained within 3 weeks of treatment commencement. Patients were reviewed weekly during cycle 1 and then every 3 weeks for safety assessment. All safety evaluations were graded according to the National Cancer Institute Common Toxicity Criteria version 2.0. Hand-foot syndrome was classified as grade 1 (numbness, dysesthesia, painless swelling, or erythema not disrupting normal activities), grade 2 (painful erythema with swelling or affecting daily living activities), or grade 3 (moist desquamation, ulceration, blistering, severe pain, or any symptoms leading to an inability to work or to perform daily living activities (25).

Sample preparation. Serum samples (stored at -80°C and transported on dry ice) were defrosted at room temperature and randomized. For each sample a 200 μL aliquot of serum was mixed with 400 μL saline (0.9% NaCl in 10% D_2O) followed by centrifugation at 16000 g for 5 minutes. 550 μL of this solution was pipetted into a 5 mm NMR tube. Samples in NMR tubes were frozen at -40°C until NMR analysis. Serum preparation was done with samples on ice.

¹H NMR Spectroscopy. All ¹H NMR spectra were acquired using a Bruker DRX600C spectrometer (Bruker Biospin, Rheinstetten, Germany), operating at a temperature of 300K, at a ¹H NMR frequency of 600.13MHz using automatic sample delivery into a 5mm TXI NMR probe. Gradient shimming was performed prior to acquisition of spectra. ¹H NMR spectra of the samples were acquired using the Carr-Purcell-Meiboom-Gill (CPMG) and 1D presaturation pulse sequences and were the sum of 256 free induction decays (FIDs) collected into 32k data-points with a spectral width of 12019.230 Hz.

Data treatment and statistical analysis. Exponential line broadening (1Hz), Fourier Transformation and manual spectral phasing and linear baseline correction were conducted using XWIN NMR 3.5 software (Bruker). Data were imported and manipulated in Matlab (Mathworks) using in-house software ‘NMRProc’ and ‘Metaspectra’ written and compiled by Dr. T.M.D. Ebbels, Dr H.C.Keun, Mr. J.T. Pearce, and Dr O. Cloarec. Two spectra were excluded due to poor spectral quality. The remaining spectra were calibrated to glucose at 5.23ppm using an automated calibration script (26), normalized (27) (by the median fold change to the median spectrum) and ‘binned’ in Matlab (this was done by selective ‘peak-picking’; the data was visually assessed and 89 metabolite resonances identified). Varying bin widths were allocated based upon metabolite resonances and regions. Binned data was exported to SIMCA (Umetrics) for multivariate analysis. For relative quantification of the individual metabolites, signals were integrated with local linear baseline correction applied.

Statistical analyses were undertaken using SPSS Statistics version 17.0 (SPSS Inc.) and Microsoft Excel. Differences between metabolite integral regions were assessed by T-test (assuming unequal variance and corrected for multiple testing, $q < 0.05$). Correlation between metabolite regions and severity of toxicity was assessed using Kendall’s tau (rank-based, 2

tailed). The criteria for metabolite selection was correspondence between visual identification of average differences in resonance intensity and spectral position of integral regions with the significance level as assessed by T-test and Kendall's tau. The relationship between metabolite signals and clinical data (BMI, weight at baseline, age, and sex) was assessed using correlation analysis (Kendall's tau).

Results

Patients and treatment outcome. NMR spectra of sufficient quality could not be obtained from two samples; therefore, metabonomic-outcome analyses were conducted on 52 patients. The demographic and clinical characteristics of the patients are summarized in Table 1. The majority of patients had liver function tests within normal range at the time of diagnosis; mean albumin 39g/L (range 29 – 46), mean bilirubin 7 μ mol/L (range 4 – 147), mean AST 23U/L (range 9 – 125), mean ALT 20U/L (range 10 – 101) and mean ALP 116U/L (range 53 – 484). Patients received 2g capecitabine twice daily as a single agent for a median duration of 3 months (range 1 - 7 months). The median number of cycles received was 4.9 (range 1-8 cycles). As previously published, the response rate to therapy was 28% (95% CI: 15.7 - 40.3) (24) .

Clinically significant toxicities are reported in Table 2. Overall, capecitabine was well tolerated with no grade 4 non-hematologic or grade 3/4 hematologic adverse events recorded. There were no adverse event–related deaths during the study. The most common treatment-related adverse events were diarrhoea, hand-foot syndrome, and fatigue. Toxicity led to the cessation of treatment in eight patients (15%) and of these, five patients ceased treatment after cycle 1. The most frequent adverse event leading to discontinuation was grade 3 diarrhoea. These patients were included in the final analysis.

Relationship between ¹H NMR metabolic profile and toxicity

We hypothesised that there is a relationship between features in the ¹H NMR metabolic profile of sera taken from patients pre-treatment, and subsequent toxicity as a result of capecitabine exposure. Figure 1 is aliphatic region of the mean CPMG spectrum of the sera collected from

patients who experienced no toxicity overlaid with the mean spectrum of sera from those who experienced severe toxicity (grade 3) over the total treatment period. The CPMG experiment attenuates signals from macromolecules, in particular serum proteins, allowing a better focus on metabolic features. Visual inspection indicated that there were major differences on average between the spectra, including resonances from lipid fatty acid chains, glutamate, glutamine, polyunsaturated fatty acids (PUFA), and choline phospholipids.

Following these initial visual indications, the CPMG spectrum for each patient was integrated at 89 targeted spectral regions encompassing resolved resonances apparent by visual inspection. As an initial test of the hypothesis, a partial least squares-discrimination analysis (PLS-DA) was performed using the integrated ^1H NMR spectral regions from patients experiencing grade 0 and grade 3 toxicity. Figure 2A shows the scores plot for the resulting model, indicating separation between the two groups and when the data for grades 1 and 2 were predicted into the model the trend was for these intermediate toxicity groups to cluster between the two extremes. This suggested that there were some features in ^1H NMR spectral profile dependent on the severity of the experienced toxicity. However the cross-validation predictivity of the model approached but did not reach significance by permutation analysis ($Q^2=0.42$, $p=0.098$), limiting the further use of the model to identify the discriminatory features. The PLS-DA loadings coefficients (Figure 2B) indicated that the resonances from lipid fatty acid chains, glutamate, polyunsaturated fatty acids (PUFA), and choline phospholipids were also influencing the multivariate model, consistent with our initial observations.

To define more precisely which spectral features were significantly associated with toxicity from capecitabine, we assessed the mean difference in intensity of each metabolite resonance (89 resonances, the same as used for the multivariate analysis) between the grade 0 and grade 3 groups. Table 3 shows the ^1H NMR resonances that were identified as being significantly different between the two patient groups. These included fatty acid chains, polyunsaturated fatty acids, choline phospholipid, valine, adipic acid, tyrosine and one unassigned resonance. We then applied the method of Benjamini and Holchberg (28) to evaluate the false discovery rate (FDR) and P-value corrected for multiple testing (q). Four spectral regions were still considered significant ($q < 0.05$) after multiple testing correction, corresponding to the following moieties; $-\text{CH}_3$ (δ 0.8-0.86); $(-\text{CH}_2)_n$ (δ 1.21-1.24); $=\text{CH}-\text{CH}_2-\text{CH}=\text{}$ (δ 2.72-2.78), and $\text{N}(\text{CH}_3)_3$ (δ 3.2-3.2). The levels of these resonances were all higher in the patients who experienced severe toxicity compared to no toxicity. These moieties were assigned to LDL-like lipid particles (δ 0.8-0.86 & 1.21-1.24), including polyunsaturated fatty acids (δ 2.72-2.78), and choline phospholipids (δ 3.2-3.22). The assignments were made on the basis of previous literature (1, 2, 29), describing variation in the frequency of lipoprotein resonances as a result of susceptibility anisotropy (example 2D NMR data is also available as supplementary data). The annotation of the ^1H NMR spectrum of human plasma and serum has been comprehensively described in many publications which show that the metabolites detectable by NMR in serum are highly consistent and that significant variation in chemical shift due to inter-sample variation in pH, temperature or ionic strength is also minimal in this biological matrix.

We also compared the CPMG spectra to those acquired using a standard pre-saturation sequence and observed a similar or lower magnitude of differences between the toxicity groups (Figure 3).

As the CPMG suppresses high-molecular weight species such lipoprotein particles, this suggested that the CH₂ and CH₃ moieties were from smaller, higher density particles such LDL, rather than very low density lipoprotein (VLDL). Finally, the fact that choline phospholipid-based and polyunsaturated fatty acid-based resonances were observed this also supports the assignment of the lipid-based resonances to LDL, as phosphatidylcholine is the main phospholipid in LDL, and the most common fatty acyl chain in LDL is from a polyunsaturated fatty acid. Despite this there is substantial evidence to suggest that NMR lipid profiles are sensitive to subtle differences in lipoprotein particle size and composition that is not reflected by conventional estimates of lipoprotein particle distribution (30, 31) and hence we define our lipid profile primarily by resonance frequency rather than lipoprotein species.

Having identified a pharmaco-metabonomic lipid profile discriminating between the most extreme toxicity groups (grade 0 and grade 3), we observed that those patients experiencing intermediate levels of toxicity (grade 1 and 2) also appeared on average to possess an intermediate spectral profile in terms of the same selected lipid resonances, and that there was a visual indication of a progression with severity of toxicity (Figure 3; Figure 4). To assess more objectively the progressive nature of the relationship between lipid profile and toxicity grade, a non-parametric correlation analysis was conducted on the resonance intensities using Kendall's tau statistic. Significant correlations ($p < 0.05$) were observed for four lipid resonances in our pharmaco-metabonomic profile (Table 2; tau 0.227-0.286) and also to a lesser extent for resonances from glutamate (δ 2.31-2.37) and unsaturated lipids/triglycerides (δ 5.26-5.36). These results support the hypothesis that a more quantitative relationship exists between the pre-treatment metabolic profile and subsequent toxicity from capecitabine.

Finally, to test if the lipid resonances in the pharmaco-metabonomic profile were providing information beyond basic anthropometric parameters, we calculated all possible non-parametric correlations between each of the four selected resonances and age, gender, BMI, and baseline body weight. Weight at baseline, but not BMI, age or gender, was inversely correlated to toxicity grade ($\tau=-0.233$), consistent with previous reports of a significant relationship between low lean body mass and increased 5-FU-induced adverse events (32). BMI and baseline weight were negatively correlated to both lipid CH_3 and $\text{N}(\text{CH}_3)_3$ resonances (-0.232 to -0.305), but not to $(-\text{CH}_2)_n$ or $=\text{CH}-\text{CH}_2-\text{CH}=\text{CH}$ resonances, and the correlation between the lipid resonances was variable (0.193-0.538). Collectively these observations indicate that the lipid profile provides information beyond basic baseline patient characteristics on the risk and possible severity of toxicity.

Discussion

In the last few years the ^1H NMR-based metabolic profiling approach has shown potential in the prediction of response to treatment (pharmaco-metabonomics) using the fate of paracetamol in rats and man as an example of the method in principle (6, 7, 33). These studies highlight the predictive potential of metabonomics-based personalised health care in a clinical setting. The current challenge is to assess how well this pharmaco-metabonomic approach translates to the clinic. A patient's response to a given chemotherapeutic treatment relies on a complex array of factors that are broadly encompassed by both the genome and environment. Unlike pharmacogenomics which focuses on the genetic/enzymatic factors in disease and drug metabolism, pharmaco-metabonomics interrogates the metabolism of a particular biofluid or tissue from a patient, providing a profile that is derived from combined genetic and environmental influences (34). The advantage of this approach is the ability to identify a downstream profile that provides a picture of the biological system in its 'current state', as opposed to a potential state (as may be indicated by a genetic factor).

Previous research using metabolic profiling of biofluids in the oncology setting has focused on identifying panels of metabolites that show potential for aiding current diagnostic methodology (11). To our knowledge this is the first study to report the predictive capacity of metabonomics to allow identification of toxicity severity secondary to chemotherapy using pre-treatment serum samples from patients with colorectal cancer. In this study we showed an association with lipid-based resonances and increased toxicity experienced by patients. This study highlights the possible role of this technique in individualizing chemotherapy regimens to avoid intolerable side-effects, thereby improving treatment outcomes.

Whilst provocative, the mechanism by which this association occurs remains to be elucidated and a number of hypotheses may account for our findings. One hypothesis may be that of inflammation. It is well established that raised levels of inflammatory markers are associated with elevated serum lipids, in particularly LDLs (35-37). Furthermore, the presence of inflammation has been shown in a number of studies to be a predictor of clinical outcome in malignancy (38-41). A number of *in vivo* studies have illustrated alteration in hepatic expression of nuclear receptors, LXR, FXR, PPAR, CAR and PXR, involved in lipid handling in the presence of inflammation (42). It is therefore plausible that the NMR signature observed in this study is a result of alteration in hepatic metabolism due to the presence of circulating pro-inflammatory cytokines. Previous work by a number of investigators suggest that the presence of extra-hepatic malignancy can impact negatively on hepatic drug metabolism; the mechanism by which this occurs remains to be elucidated but is postulated to be the presence of inflammation (43)(44, 45). Furthermore, previous reports utilizing the lipid lowering agent, omega-3 fatty acids, as an adjunct to chemotherapy, has shown these to be beneficial in reducing toxicity from chemotherapy in colorectal cancer patients, and this has been attributed to the anti-inflammatory effect of these interventions, rather than the lipid lowering effects of the fatty acids (46). This again lends support to the hypothesis that abnormal lipid profiles may reflect inflammation secondary to malignancy. Serum lipids as a predictor of either toxicity or response have not been studied in oncology as lipids are not routinely measured in patients with malignancy and this remains an open area of investigation.

A further hypothesis for our findings is the impact of lipids on the protein binding of capecitabine itself and its metabolites. Protein binding strongly influences a drug's distribution and/or clearance, and a number of studies have illustrated altered protein binding in patients with type II diabetes and hyperlipidaemia (47-49). Lipids are known to interact directly with proteins to alter their capacity for drug binding via competitive or allosteric modulation. Capecitabine is relatively hydrophobic in comparison to its metabolites, and it is possible that patients with raised lipids may have a greater circulating pool of capecitabine and therefore may experience greater drug exposure. Future studies should incorporate first dose PKs of capecitabine and its metabolites to further investigate this hypothesis, as it is possible that the association between pre-treatment serum lipid profiles and the level of toxicity experienced in this patient cohort may represent subtle differences in lipid-based metabolism that result in altered clearance in capecitabine, or its metabolites, leading to the differences in toxicity reported.

Previous meta-analysis identified poor performance status, age greater than 70 and female gender as predictors of toxicity to single agent 5-FU (50)(51). However, there have been no studies in patients with metastatic colorectal cancer investigating BMI or base weight as predictors of toxicity. A number of papers have shown that in the adjuvant setting, a BMI of greater than 30 is predictive of worse toxicity (52, 53). However, there are a number of limitations relating to BMI mainly that it is entirely based on a Caucasian population and may not relate to other ethnicities, which contributed to our study population. Furthermore, BMI does not consider the physiological state of the patient which is important particularly in patients with malignancy. Other anthropometric measures have been suggested to be more accurate in determining body composition and a study by Prado and colleagues found an association

between low lean body mass, as measured by CT, and worse toxicity with 5-FU, lending support to our findings (32). Therefore, whilst our findings of weight and toxicity are interesting they raise the need further investigation with more detailed anthropometric measures in a larger patient population.

We chose to study the metabonomic profile of patients prior to receiving capecitabine with the primary aim to identify a metabonomic profile predictive of toxicity. Whilst these results are provocative they need to be validated in larger confirmatory studies. The results of this study will act as a training set that will be validated in a larger patient group to confirm the utility of metabonomics as a predictor of toxicity prior to patients receiving chemotherapy. From this planned future study it will be possible to more accurately define specific cut-off values for spectral species above which patients presenting to the clinic would be likely to experience toxicity. Chemotherapy doses could then be prospectively altered. These studies will be difficult to conduct with single agent capecitabine as combination therapy now remains the mainstay of treatment in colorectal cancer, and furthermore individual drugs themselves may impact on the metabonomic profiles. For example there have been several reported incidences of patients treated with capecitabine developing hypertriglyceridemia which would influence post-therapy profiles obtained (54-58). How these drug effects are treated remains to be considered. In future studies it would also be of interest to investigate impact of chemotherapy on the metabonomic profile by considering pre- and post-treatment NMR spectra, and correlating any change with clinical outcome.

Chemotherapy-induced toxicities have direct impact on cancer treatment outcomes including response rates and survival (59). Moreover, adverse effects not only limit the ability of the oncologist to effectively deliver treatment, but they also have a significant negative impact on the patient's quality of life (60-62). It can be argued that a significant level of toxicity is acceptable if the ultimate goal of treatment is cure, however severe treatment related toxicity is unacceptable where the objective of treatment is symptom palliation (63, 64). The use, therefore, of serum metabonomics as a non-invasive tool for the prediction of toxicity could greatly benefit this patient population and these data require further investigation prospectively in a large clinical trial. The next step in the process of defining a predictive set of markers is to move to a much larger patient cohort to generate predictive models with training and validation sets. In all such predictive studies there remains the challenge of balancing findings identified in populations, e.g. geographical differences in folate intake, versus those derived from the study of inter-individual differences. Our eventual goal is to produce models based on the combination of both pharmaco-genetic and pharmaco-metabonomic information using up- and down-stream data to help delineate the optimum therapeutic pathway for the individual patient(65)(66).

References

1. Nicholson JK, Foxall PJ, Spraul M, Farrant RD, Lindon JC. 750 MHz ^1H and ^1H - ^{13}C NMR spectroscopy of human blood plasma. *Anal Chem* 1995;67:793-811.
2. Ala-Korpela M. ^1H NMR spectroscopy of human blood plasma. *Progress in Nuclear Magnetic Resonance Spectroscopy* 1995;27:475.
3. Beckonert O, Keun HC, Ebbels TMD, Bundy J, Holmes E, Lindon JC, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. *Nat Protocols* 2007;2:2692-703.
4. Fan TWM. Metabolite profiling by one- and two-dimensional NMR analysis of complex mixtures. *Progress in Nuclear Magnetic Resonance Spectroscopy* 1996;28:161-219.
5. Clayton AT, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, et al. Pharmacometabonomic phenotyping and personalized drug treatment. *Nature* 2006;440:1073-7.
6. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. *Proceedings of the National Academy of Sciences* 2009; 106:14728-33
7. Winnike JH, Li Z, Wright FA, Macdonald JM, O'Connell TM, Watkins PB. Use of Pharmacometabonomics for Early Prediction of Acetaminophen-Induced Hepatotoxicity in Humans. *Clin Pharmacol Ther* 2010;88:45-51.

8. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* 2009;462:739-44.
9. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. *Nature* 2009;457:910-4.
10. Bathen TF, Sitter B, Sjobakk TE, Tessem M-B, Gribbestad IS. Magnetic Resonance Metabolomics of Intact Tissue: A Biotechnological Tool in Cancer Diagnostics and Treatment Evaluation. *Cancer research* 2010;70:6692-6
11. Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, Tammela J, et al. Detection of epithelial ovarian cancer using ^1H NMR-based metabolomics. *International Journal of Cancer* 2005;113:782-8.
12. Tiziani S, Lopes V, Gunther UL. Early stage diagnosis of oral cancer using ^1H NMR-based metabolomics. *Neoplasia* 2008;11:269-76.
13. MacIntyre DA, Jimenez B, Lewintre EJ, Martin CR, Schafer H, Ballesteros CG, et al. Serum metabolome analysis by ^1H -NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. *Leukemia* 2010;24:788-97.
14. Keun HC, Sidhu J, Pchejetski D, Lewis JS, Marconell H, Patterson M, et al. Serum Molecular Signatures of Weight Change during Early Breast Cancer Chemotherapy. *Clinical Cancer Research* 2009;15:6716-23.

15. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. *Eur J Cancer* 1998;34:1274-81.
16. Shimma N, Umeda I, Arasaki M, Murasaki C, Masubuchi K, Kohchi Y, et al. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine. *Bioorg Med Chem* 2000;8:1697-706.
17. Tabata T, Katoh M, Tokudome S, Hosakawa M, Chiba K, Nakajima M, et al. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation. *Drug Metab Dispos* 2004;32:762-7.
18. Tabata T, Katoh M, Tokudome S, Nakajima M, Yokoi T. Identification of the cytosolic carboxylesterase catalyzing the 5'-deoxy-5-fluorocytidine formation from capecitabine in human liver. *Drug Metab Dispos* 2004;32:1103-10.
19. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. *J Clin Oncol* 2008;26:2006-12.
20. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. *J Clin Oncol* 2007;25:4217-23.

21. Diaz-Rubio E, Taberero J, Gomez-Espana A, Massuti B, Sastre J, Chaves M, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. *J Clin Oncol* 2007;25:4224-30.
22. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. *Br J Cancer* 2004;90:1190-7.
23. Twelves C, Wong A, Nowacki MP, Abt M, Burris H, 3rd, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. *N Engl J Med* 2005;352:2696-704.
24. Sharma R, Rivory L, Beale P, Ong S, Horvath L, Clarke SJ. A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. *The British Journal of Cancer* 2006;94:964.
25. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer. *J Clin Oncol* 1999;17:485-93.
26. Pearce JTM, Athersuch TJ, Ebbels TMD, Lindon JC, Nicholson JK, Keun HC. Robust Algorithms for Automated Chemical Shift Calibration of 1D ¹H NMR Spectra of Blood Serum. *Analytical chemistry* 2008;80:7158-62.

27. Dieterle F, Ross A, Schlotterbeck G, Senn H. Probabilistic Quotient Normalization as Robust Method to Account for Dilution of Complex Biological Mixtures. Application in ^1H NMR Metabonomics. *Analytical chemistry* 2006;78:4281-90.
28. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B (Methodological)* 1995;57:289-300.
29. Tukiainen T, Tynkkynen T, Mäkinen V-P, Jylänki P, Kangas A, Hokkanen J, Vehtari A, et al. A multi-metabolite analysis of serum by ^1H NMR spectroscopy: Early systemic signs of Alzheimer's disease. *Biochemical and Biophysical Research Communications* 2008;375:356-61.
30. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, et al. Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. *Circulation* 2006;113:1556-63.
31. Otvos J, Jeyarajah E, Bennett D, Krauss R. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. *Clin Chem* 1992;38:1632-8.
32. Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. *Clin Cancer Res* 2007;13:3264-8.

33. Andrew Clayton T, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. *Nature* 2006;440:1073-7.
34. Nicholson JK. Global systems biology, personalized medicine and molecular epidemiology. *Mol Syst Biol* 2006;2:52
35. Krauss RM, Winston M, Fletcher RN, Grundy SM. Obesity: impact of cardiovascular disease. *Circulation* 1998;98:1472-6.
36. Denke MA, Sempos CT, Grundy SM. Excess body weight. An under-recognized contributor to dyslipidemia in white American women. *Arch Intern Med* 1994;154:401-10.
37. Despres JP, Moorjani S, Tremblay A, Ferland M, Lupien PJ, Nadeau A, et al. Relation of high plasma triglyceride levels associated with obesity and regional adipose tissue distribution to plasma lipoprotein-lipid composition in premenopausal women. *Clin Invest Med* 1989;12:374-80.
38. Richards CH, Leitch EF, Horgan PG, Anderson JH, McKee RF, McMillan DC. The relationship between patient physiology, the systemic inflammatory response and survival in patients undergoing curative resection of colorectal cancer. *Br J Cancer* 2010;103:1356-61.
39. Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. *Cancer* 2008;112:2377-83.

40. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhaus ML, Wener MH, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. *J Clin Oncol* 2009;27:3437-44.
41. Ishizuka M, Kita J, Shimoda M, Rokkaku K, Kato M, Sawada T, et al. Systemic inflammatory response predicts postoperative outcome in patients with liver metastases from colorectal cancer. *J Surg Oncol* 2009;100:38-42.
42. Stedman CAM, Liddle C, Coulter SA, Sonoda J, Alvarez JGA, Moore DD, et al. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. *Proceedings of the National Academy of Sciences of the United States of America* 2005;102:2063-8.
43. Aitken AE, Richardson TA, Morgan ET. Regulation of drug metabolising enzymes and transporters in inflammation. *Annu Rev Pharmacol Toxicol* 2006;46:123-49.
44. Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, Robertson GR. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. *Clin Cancer Res* 2006;12:7492-7.
45. Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ, et al. Factors affecting cytochrome P-450 3A activity in cancer patients. *Clin Cancer Res* 2004;10:8341-50.
46. Read J, Beale PJ, Volker DH, Smith N, Childs A, Clarke SJ. Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal

cancer. Effects on nutritional and inflammatory status: a phase II trial. *Supportive care in cancer* 2007;15:301-7.

47. Ruiz-Cabello F, Erill S. Abnormal serum protein binding of acidic drugs in diabetes mellitus. *Clin Pharmacol Ther* 1984;36:691-5.

48. Anger GJ, Piquette-Miller M. Impact of hyperlipidemia on plasma protein binding and hepatic drug transporter and metabolic enzyme regulation in a rat model of gestational diabetes. *J Pharmacol Exp Ther* 2010;334:21-32.

49. de la Fuente L, Lukas JC, Jauregizar N, Vazquez JA, Calvo R, Suarez E. Prediction of unbound propofol concentrations in a diabetic population. *Ther Drug Monit* 2002;24:689-95.

50. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. *J Clin Oncol* 1998;16:3537-41.

51. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. *Cancer* 1995;75:11-7.

52. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Benson AB, 3rd, Macdonald JS, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. *Cancer* 2003;98:484-95.

53. Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, McCollum AD, Brady D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. *J Clin Oncol* 2004;22:648-57.
54. Kurt M, Babaoglu MO, Yasar U, Shorbagi A, Guler N. Capecitabine-Induced Severe Hypertriglyceridemia: Report of Two Cases. *Ann Pharmacother* 2006;40:328-31.
55. Bar-Sela G, Haim N. Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature. *Cancer Chemotherapy and Pharmacology* 2009;63:779-82.
56. Orphanos GS, Stavrou NG, Picolos MK. Hypertriglyceridemia: An underdiagnosed side effect of Capecitabine chemotherapy. *Acta oncologica* 2010;49:262-3.
57. Koutras AK, Habeos IG, Vagenakis AG, Kalofonos HP. Capecitabine-induced Hypertriglyceridemia: A Report of Two Cases. *Anticancer Research* 2006;26:2249-51.
58. Stathopolous GP, Koutanos J, Lazaki H, Rigatos SK, Stathopoulos J, Deliconstantinos G. Capecitabine (Xeloda) as Monotherapy in Advanced Breast and Colorectal Cancer: Effectiveness and Side-effects. *Anticancer Research* 2007;27:1653-6.
59. Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P, et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. *Br J Cancer* 1989;59:287-90.
60. Gunnars B, Nygren P, Glimelius B. Assessment of Quality of Life During Chemotherapy. *Acta oncologica* 2001;40:175-84.

61. Gridelli C. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer? *Lung Cancer* 2002;38:45-50.
62. Georges J-J, Onwuteaka-Philipsen BD, van der Heide A, van der Wal G, van der Maas PJ. Symptoms, treatment and “dying peacefully” in terminally ill cancer patients: a prospective study. *Supportive care in cancer* 2005;13:160-8.
63. Koedoot CG, de Haan RJ, Stiggelbout AM, Stalmeier PFM, de Graeff A, Bakker PJM, et al. Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice. *Br J Cancer* 2003;89:2219-26.
64. Rose JH, O'Toole EE, Dawson NV, Lawrence R, Gurley D, Thomas C, et al. Perspectives, Preferences, Care Practices, and Outcomes Among Older and Middle-Aged Patients With Late-Stage Cancer. *J Clin Oncol* 2004;22:4907-17.
65. Haller DG, Cassidy J, Clarke S, Cunningham D, Van Cutsem E, Hoff P, et al. Tolerability of fluoropyrimidines appears to differ by region. *J Clin Oncol (Meeting Abstracts)* 2006;24:3514.
66. Dumas M-E, Barton RH, Toyne A, Cloarec O, Blancher C, Rothwell A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. *Proceedings of the National Academy of Sciences* 2006;103:12511-6.

Acknowledgements

Lynn Maslen, Maciej Kaliszczak, Eric Aboagye

AJB was supported by the UK Medical Research Council (MRC)

Figure Legends

Figure 1 Metabonomic analysis reveals a metabolic signature associated with capecitabine toxicity. Overlay of mean ^1H NMR CPMG spectra from the patient groups who experienced no toxicity (grade 0, solid line) and those that experienced severe toxicity (grade 3, dashed line).

Figure 2 Partial least squares-discriminant analysis (PLS-DA) models of grade 0 (no toxicity, $n=3$, circles) and grade 3 (severe, $n=9$, squares) toxicity. (A) Scores plot from the 2 component PLS-DA model, showing the grade 1 and 2 data (mild + moderate) predicted using the model. (B) The PLS-DA loadings coefficients most influential on the model. The magnitude of the coefficients corresponds to the importance of a particular resonance in explaining the toxicity status. R^2X , R^2Y , and Q^2 for the model are 0.417, 0.917 and 0.42, respectively. Data were UV scaled. Permutation analysis $p=0.098$ (supplementary figure 1)

Figure 3 Comparison of the mean 1D presaturation and CPMG spectra for each toxicity grade for (A) fatty acid chain, and (B) choline phospholipid spectral regions.

Figure 4 The metabolites that differ significantly between patients that consequently experience no toxicity and those that experience a severe response show intermediate levels in the patients that experience mild and moderate toxicity (grade 1 and 2). In all cases $p<0.05$ for both Kendall's tau across all toxicity grades, and a T test comparing no toxicity (grade 0) and severe groups (grade 3)

Table 1 Demographic and clinical characteristics (n=52)

Characteristic	No. of patients (%)
Male	34 (65)
Median age, yrs (range)	79 (42 - 86)
Median bodyweight, kg (range)	70 (40 – 117)
Performance status	
0	18 (35)
1	32 (62)
2	2 (4)
Primary tumour site	
Colon	38 (73)
Rectal	14 (27)
No. of metastatic sites	
1	31 (60)
2	15 (29)
≥3	6 (11)
Prior adjuvant chemotherapy	12 (23)
Prior chemotherapy for metastatic disease	2 (4)
Prior pelvic radiotherapy	6 (12)

Table 2 Grade 2 and 3 adverse events experienced by patients over the study period. All safety evaluations were graded according to the National Cancer Institute Common Toxicity Criteria version 2.0 (n=52).

Toxicity[§]	% of patients	
	Grade 2	Grade 3
Fatigue	25	2
Hand-foot syndrome	11	11
Stomatitis	15	0
Diarrhea	25	9
Nausea and vomiting	9	2
Anaemia	13	0
Bilirubin	4	0

Table 3 Spectral regions from pre-treatment serum associated with the level of toxicity experienced in patients receiving fixed-dose capecitabine

¹ H shift (ppm)	multiplicity	molecule	assignment	% change from grade 0 toxicity			Grade 0 toxicity versus grade 3	correlation with grades 0-4
				Grade 1 (n=9)	Grade 2 (n=26)	Grade 3 (n=9)	t-test p value (q-value)	Kendall's tau (p-value)
0.8-0.86	m	lipid, fatty acid chain	-CH ₃	47.3	49.3	70.1	0.0012 (0.027) **	0.271 (0.018*)
1.21-1.235	m	lipid, fatty acid chain	(-CH ₂) _n	35.6	38.4	53.9	<0.001 (0.006) ***	0.265 (0.021*)
2.720-2.780	m	PUFA	-CH-CH ₂ -CH=	66.2	67.6	117.8	<0.001 (0.021) ***	0.227 (0.047*)
3.2-3.22	m	choline phospholipid	-N(CH ₃) ₃	45.0	53.5	71.6	0.001 (0.03) **	0.286 (0.013*)
1.235-1.295	m	lipid, fatty acid chain	(CH ₂ CH ₂ CH ₂) _n	44.5	75.9	103.0	<0.01 (0.14)	0.227 (<0.05*)
0.99	d	valine	-CH ₃	20.1	19.9	23.2	<0.01 (0.14)	0.113 (0.323)
7.2-7.3	m	unassigned	-	-23.8	-21.7	-36.0	0.011 (0.14)	-0.224 (0.051)
1.57	m	adipic acid	CH ₂ CH ₂ CO	851.7	590.5	263.8	0.014 (0.16)	0.132 (0.250)
6.88	d	tyrosine	H3, H5	-23.4	-18.5	-32.1	<0.05 (>0.20)	-0.157 (0.169)
2	m	lipid, fatty acid chain	CH ₂ C=C	8.4	14.3	23.5	<0.05 (>0.20)	0.169 (0.140)

Spectral regions were screened using a T test comparing the patients that experienced no toxicity versus severe toxicity (2 tailed, assuming unequal variance and corrected for multiple testing, q<0.05). These regions were then tested for correlation across all four

toxicity grades using Kendall's tau (rank-based correlation, 2 tailed). Tests were considered significant at the following levels:

*** $p \leq 0.001$, ** $p \leq 0.01$, * $p \leq 0.05$ after correction for multiple testing; PUFA, polyunsaturated fatty acid

Figure 1




Figure 2




Figure 3




Figure 4




Table 1 Demographic and clinical characteristics (n=52)	
Characteristic	No. of patients (%)
Male	34 (65)
Median age, yrs (range)	79 (42 - 86)
Median bodyweight, kg (range)	70 (40 – 117)
Performance status	
0	18 (35)
1	32 (62)
2	2 (4)
Primary tumour site	
Colon	38 (73)
Rectal	14 (27)
No. of metastatic sites	
1	31 (60)
2	15 (29)
≥3	6 (11)
Prior adjuvant chemotherapy	12 (23)
Prior chemotherapy for metastatic disease	2 (4)
Prior pelvic radiotherapy	6 (12)

Table 2 Grade 2 and 3 adverse events experienced by patients over the study period. All safety evaluations were

Toxicity	% of patients	
	Grade 2	Grade 3
Fatigue	25	2
Hand-foot syndrome	11	11
Stomatitis	15	0
Diarrhea	25	9
Nausea and vomiting	9	2
Anaemia	13	0
Bilirubin	4	0

graded according to the National Cancer Institute Common Toxicity Criteria version 2.0 (n=52).

Table 3 Spectral regions from pre-treatment serum associated with the level of toxicity experienced in patients receiving fixed-

¹ H shift		% change from grade 0 toxicity			Grade 0 toxicity versus grade 3		
(ppm)	multiplicity	molecule	assignment	Grade 1 (n=9)	Grade 2 (n=26)	Grade 3 (n=9)	t-test p value (q-value)
0.8-0.86	m	lipid, fatty acid chain	0	47.3	49.3	70.1	0.0012 (0.027) **
1.21-1.235	m	lipid, fatty acid chain	(-CH ₂) _n	35.6	38.4	53.9	<0.001 (0.006) ***
2.720-2.780	m	PUFA	-CH-CH ₂ -CH=	66.2	67.6	117.8	<0.001 (0.021) ***
3.2-3.22	m	choline phospholipid	-N(CH ₃) ₃	45	53.5	71.6	0.001 (0.03) **
1.235-1.295	m	lipid, fatty acid chain	(CH ₂ CH ₂ CH ₂) _n	44.5	75.9	103	<0.01 (0.14)
0.99	d	valine	0	20.1	19.9	23.2	<0.01 (0.14)
7.2-7.3	m	unassigned	-	-23.8	-21.7	-36	0.011 (0.14)
1.57	m	adipic acid	CH ₂ CH ₂ CO	851.7	590.5	263.8	0.014 (0.16)
6.88	d	tyrosine	H3, H5	-23.4	-18.5	-32.1	<0.05 (>0.20)
2	m	Lipid, fatty acid chain	CH ₂ C=C	8.4	14.3	23.5	<0.05 (>0.20)

Spectral regions were screened using a T test comparing the patients that experienced no toxicity versus severe toxicity (2 tail variance and corrected for multiple testing, q<0.05). These regions were then tested for correlation across all four toxicity grades (1 based correlation, 2 tailed). Tests were considered significant at the following levels: ***p≤0.001, **p≤0.01, *p≤0.05 after correction. PUFA, polyunsaturated fatty acid

dose capecitabine

correlation with grades 0-4
Kendall's tau (p-value)
0.271 (0.018*)
0.265 (0.021*)
0.227 (0.047*)
0.286 (0.013*)
0.227 (<0.05*)
0.113 (0.323)
-0.224 (0.051)
0.132 (0.250)
-0.157 (0.169)
0.169 (0.140)

ed, assuming unequal
using Kendall's tau (rank-
tion for multiple testing;

Clinical Cancer Research

Pharmaco-metabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine

Alexandra Backshall, Rohini Sharma, Stephen Clarke, et al.

Clin Cancer Res Published OnlineFirst March 17, 2011.

Updated version	Access the most recent version of this article at: doi: 10.1158/1078-0432.CCR-10-2474
Supplementary Material	Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2011/05/05/1078-0432.CCR-10-2474.DC1
Author Manuscript	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/early/2011/03/16/1078-0432.CCR-10-2474 . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.